Shilpa Medicare gets Code J for Pemetrexed Injection
Shilpa's - NDA Pemetrexed Injection, is a novel ready-to-use injection which eliminates the need for reconstitution and dilution before administration to the patient.
Karnataka: Shilpa Medicare has announced that the Company's NDA Product PEMRYDI RTU (Pemetrexed injection 10 mg/mL), has received from the U.S. Centers for Medicare & Medicaid Services (CMS) an exclusive product-specific code J.
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin and has market size of US $ 293 million as per IQVIA MAT Q3 2023.
Shilpa’s - NDA Pemetrexed Injection, is a novel ready-to-use injection which eliminates the need for reconstitution and dilution before administration to the patient. This ready-to-use formulation enables reduction of dosing errors, ease of administration and accurate dosing based on patient body weight.
J-codes are permanent reimbursement codes used by healthcare providers, government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a healthcare professional. J-codes simplify and streamline the billing and reimbursement processes, allowing for efficient claims processing resulting in significant conveniences to the patient. Code “J” enables marketing the product as a niche product.
Shilpa has already signed with the US partner for launching this product in the US market and will be launched in Q-1 of 2024.
Read also: Shilpa Medicare Jadcherla facility clears TGA, Australia GMP inspection
Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.